Signal active
Organization
Contact Information
Overview
Rheonix, Inc. operates as a biomedical device company. Its products include CARD (Chemistry And Reagent Device) system to miniaturize and automate new and existing assays in multiple fields. Its products and technology are used in human/veterinary in vitro diagnostics, food/water testing, SNP analysis for personalized medicine applications, homeland security/defense applications, process control and final product QC, and tissue culture analysis in a research or production setting. Rheonix, Inc. was founded in 2007 and is based in Ithaca, New York.
About
Biotechnology, Health Care, Medical Device, Homeland Security, Health Diagnostics
2007
51-100
Headquarters locations
New York, United States, North America
Social
N/A
Profile Resume
Rheonix headquartered in New York, United States, North America, operates in the Biotechnology, Health Care, Medical Device, Homeland Security, Health Diagnostics sector. The company focuses on Biotechnology and has secured $19.1B in funding across 220 round(s). With a team of 51-100 employees, Rheonix is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Rheonix, raised $12.6M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
11
1
0
$86.7M
Details
2
Rheonix has raised a total of $86.7M in funding over 2 rounds.
Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
---|---|---|---|---|
2013 | Early Stage Venture | |||
2010 | Early Stage Venture | 12.6M |
Investors
Rheonix is funded by 10 investors.
Investor Name | Lead Investor | Funding Round | Partners |
---|---|---|---|
Onondaga Venture Capital Fund | - | FUNDING ROUND - Onondaga Venture Capital Fund | 28.6M |
Allen F. “Pete” Grum | - | FUNDING ROUND - Allen F. “Pete” Grum | 28.6M |
Rheonix | - | FUNDING ROUND - Rheonix | 28.6M |
Rand Capital | - | FUNDING ROUND - Rand Capital | 28.6M |
Recent Activity
There is no recent news or activity for this profile.